Comparative Pharmacology
Head-to-head clinical analysis: AMLODIPINE BESYLATE BENAZEPRIL HYDROCHLORIDE versus PRINZIDE.
Head-to-head clinical analysis: AMLODIPINE BESYLATE BENAZEPRIL HYDROCHLORIDE versus PRINZIDE.
AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE vs PRINZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amlodipine is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions into vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced peripheral vascular resistance. Benazepril is an angiotensin-converting enzyme (ACE) inhibitor that prevents the conversion of angiotensin I to angiotensin II, resulting in vasodilation, decreased aldosterone secretion, and reduced blood pressure.
PRINZIDE is a combination of lisinopril (an ACE inhibitor) and hydrochlorothiazide (a thiazide diuretic). Lisinopril inhibits angiotensin-converting enzyme, reducing angiotensin II formation, leading to vasodilation and decreased aldosterone secretion. Hydrochlorothiazide inhibits sodium and chloride reabsorption in the distal convoluted tubule, promoting diuresis and reducing plasma volume.
Oral, 1 capsule (amlodipine 2.5-10 mg / benazepril 10-40 mg) once daily. Start with amlodipine 2.5 mg / benazepril 10 mg, titrate based on response.
Oral, 1-2 tablets daily; each tablet contains 25 mg hydrochlorothiazide and 5 mg lisinopril. Adjust based on blood pressure response; maximum daily dose: 2 tablets.
None Documented
None Documented
Amlodipine: terminal elimination half-life 30-50 hours (mean ~35 h), allowing once-daily dosing. Benazeprilat: effective half-life 10-11 hours; terminal half-life ~22 hours, with prolonged effects in renal impairment.
Lisinopril: terminal half-life 12 hours (effective half-life 30 hours due to prolonged ACE binding). Hydrochlorothiazide: terminal half-life 6-15 hours (biphasic, initial phase 2-4 h, terminal phase 6-15 h) with prolonged terminal phase in renal impairment.
Amlodipine: ~90% metabolized to inactive metabolites, ~10% excreted unchanged in urine; metabolites excreted renally (~60%) and fecally (~20-25%). Benazepril: hydrolyzed to benazeprilat, which undergoes renal excretion (~33% as unchanged drug and metabolites) and biliary/fecal excretion (~33%), with the remainder via other routes.
Lisinopril is excreted unchanged in urine (100% renal elimination); hydrochlorothiazide is excreted 95% renally as unchanged drug and 5% via bile.
Category D/X
Category C
ACE Inhibitor
ACE Inhibitor / Diuretic Combination